On Jan. 30, 2014 the U.S. Judicial Panel on Multidistrict Litigation (JPML) will begin to hear oral arguments regarding potential consolidation of all federal Lipitor lawsuits filed by women who claim their diabetes is a side effect of the drug into a multidistrict litigation (MDL).
At this time, the federal court system holds more than 100 personal injury lawsuits filed against Pfizer by women who allege they were not adequately warned about the link between Lipitor and diabetes.
This is not the first time Lipitor MDL is under consideration. A second motion to establish a Lipitor MDL was filed in October 2013. With the centralization of all federal Lipitor lawsuits into MDL, all cases would be heard before the same judge for pretrial proceedings. The goal of MDL is to serve the convenience of all parties involved, reduce duplicative discovery and avoid conflicting pretrial rulings.
At the time of the most recent petition for MDL, the JPML denied the request because there were not enough federal Lipitor lawsuits in progress. There has been a marked increase in the number of federal Lipitor lawsuits since that time, however, and the JPML will hear arguments on the matter at the U.S. Courthouse in New Orleans beginning Jan. 30, according to a recent Notice of Hearing Session.
Lipitor (atorvastatin) is one of the most highly-prescribed medications in the United States and is used to help control high cholesterol. In recent years, attention has been drawn to an association between Lipitor and an increased risk of developing diabetes. The FDA released heightened warnings about the link between Lipitor and other statins and diabetes in February 2012.
Since 1996, Lipitor sales have generated more than $125 billion for Pfizer. This widespread use of the drug may prompt additional lawsuits in the months and years to come.
If you were diagnosed with diabetes after taking Lipitor, you could be entitled to compensation. For a free consultation, please contact an experienced personal injury lawyer at Berkowitz and Hanna LLC. Our Connecticut personal injury lawyers represent individuals affected by defective and dangerous drugs.